Abstract
1. Biotechnologically-derived pharmaceuticals possess unique and often species-specific biological characteristics. Their preclinical safety evaluation therefore presents unusual challenges that often preclude strict adherence to regulatory guidelines established for small-molecular-weight compounds.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cowgill LD (1992). Pathophysiology and management of anemia in chronic progressive renal failure. Seminars in Veterinary and Medical Surgery (Small Animal), 7(3): 175–182.
Dempster AM (1995). Pharmacological testing of recombinant human erythropoietin: implications for other biotechnology products. Drug Development Research, 35:173–178.
Raine AEG (1988). Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet, 1(8557): 97–100.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Dempster, M. (1998). Designing non-clinical safety evaluation programmes: The view of the toxicologist. In: Griffiths, S.A., Lumley, C.E. (eds) Safety Evaluation of Biotechnologically-derived Pharmaceuticals. CMR International Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4876-4_2
Download citation
DOI: https://doi.org/10.1007/978-94-011-4876-4_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6043-1
Online ISBN: 978-94-011-4876-4
eBook Packages: Springer Book Archive